secwatch.observer — SEC 8-K summary
======================================

Issuer:     USANA HEALTH SCIENCES INC (USNA)
CIK:        0000896264
Form:       8-K
Filed at:   2022-02-08T23:59:59+00:00
Accession:  0001157523-22-000158
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USANA Q4 net sales $267M (-14% YoY), EPS $1.03; FY22 guidance $5.25-$6.00 EPS
-----------------------------------------------------------------------------

- Q4 net sales $267.3M (-14% YoY), diluted EPS $1.03 (-45% YoY); active customers 560K (-7% YoY).
- FY2021 net sales $1.186B (+5% YoY); diluted EPS $5.73 (-2% YoY); FX benefit $53.6M.
- FY2022 guidance: net sales $1.125-$1.225B; diluted EPS $5.25-$6.00; expects net sales acceleration.
- Q4 regional: Asia Pacific -15%, Americas/Europe -11%; COVID disruptions hurt key markets; Southeast Asia Pacific -26%.
- Ended Q4 with $240M cash, no debt; repurchased 296K shares for $28.9M; $108M buyback remaining.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/0001157523-22-000158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896264/000115752322000158/a52576017.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer